Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

Mesalazine 1,600-mg formulation noninferior to 400 mg for induction treatment of UC

01 Aug 2017

In patients with ulcerative colitis (UC), induction treatment with 3.2 mg mesalazine using two 1,600 mg tablets once-daily is as good as using four 400 mg tablets twice-daily, according to the results of a noninferority trial.

A total of 817 patients with mild-to-moderate active UC (Mayo Clinic Score >5) were treated with 3.2 g of oral mesalazine, administered as either two 1,600 mg tablets once or four 400 mg tablets twice daily. Outcomes investigated were induction of clinical and endoscopic remission at week 8. Based on response, open-label treatment with the 1,600 mg tablet continued for 26 to 30 weeks. Predictors of treatment response were also examined.

At week 8, remission occurred in 22.4 percent of patients receiving the 1,600 mg formulation and in 24.6 percent of those receiving the 400 mg formulation (absolute difference, −2.2 percent; 95 percent CI, −8.1 to 3.8; noninferiority, p=0.005). Clinical remission was significantly associated with endoscopic and histopathologic disease activity (p=0.022 and p=0.042), leucocyte concentration (p=0.014), and age (p=0.023).

At week 38, 296 of 675 patients (43.9 percent) who continued treatment with the 1,600 mg formulation were in remission, including 142 of 202 patients (70.3 percent) who received a reduced dose of mesalazine (1.6 g/d). Overall incidence of serious adverse events was low.

Oral mesalazine is the most commonly prescribed medication for patients with mild-to-moderate UC. While multitablet regimens administered two to four times daily have been shown to be safe and effective, a high-concentration formulation was developed to improve dosing convenience and ensure consistent drug release within the colon. [Gastroenterology 2015;148:1035-1058; Cochrane Database Syst Rev 2016;4:CD000543]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.